CRISPR-based Gene Editing Market Size & Growth Forecast 2027–2036, By Segments (End Use, Product & Service, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
CRISPR-based Gene Editing Market size was worth USD 5.1 billion in 2026 and is expected to grow at a 14.06% CAGR between 2027 and 2036, attaining USD 19.01 billion by 2036. The industry revenue for 2027 is estimated at USD 5.7 billion.
Get more details on this report
Request Free Sample ReportCRISPR-based Gene Editing Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 44.10% share driven by concentrated biotech firms strong academic research centers and funding that accelerates CRISPR from research into clinical and drug development applications
- Asia Pacific is projected at 16.24% CAGR supported by rising research intensity and expanding adoption of CRISPR tools across disease modeling agricultural genomics and therapeutic research applications
Segment Momentum
- Pharmaceutical & Biotechnology Companies lead with a 48.99% share, driven by their direct integration of CRISPR into drug discovery, preclinical pipelines, and ownership of long-cycle R&D programs with strong IP control.
- Contract Research Organizations are the fastest-growing segment as they provide flexible, expert-driven CRISPR execution for complex screening and validation, helping firms scale research without building full in-house capabilities.
Market Expansion Drivers
- Rising genetic disorder prevalence and biotech investment accelerating CRISPR adoption.
- Government funding and supportive regulatory frameworks boosting gene editing research.
- Expansion of clinical gene therapy pipelines driving commercialization of CRISPR technologies.
Leading Market Participants
- Prominent companies in the CRISPR-based gene editing market include Thermo Fisher Scientific Inc. (United States), Merck KGaA (Germany), Danaher Corporation (United States), Revvity, Inc. (United States), GenScript Biotech Corporation (China), Bio-Rad Laboratories, Inc. (United States), Bio-Techne Corporation (United States), New England Biolabs, Inc. (United States), OriGene Technologies, Inc. (United States), Integrated DNA Technologies, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 5.1 billion
- 2027 Estimated Market Size: USD 5.7 billion.
- Projected Market Size: USD 19.01 billion by 2036
- Growth Forecast: 14.06% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Pharmaceutical & Biotechnology Companies (End Use) | Products (Product & Service) | Biomedical (Application)
- Emerging Opportunity Segment: Contract Research Organizations (End Use) | Services (Product & Service) | Biomedical (Application)
Market Growth Drivers and Industry Trends
Rising genetic disorder prevalence and biotech investment accelerating CRISPR adoption
The growing burden of genetic disorders is increasing demand for precise therapeutic approaches, supporting expansion of the CRISPR-based gene editing market. CRISPR technologies enable researchers to target specific genetic sequences and investigate or modify disease-associated mutations, making the platform valuable across the development of treatments for inherited conditions. At the same time, rising investment in biotechnology is supporting laboratory research, platform development, and translation of gene-editing discoveries into therapeutic programs. Greater availability of specialized research capabilities and funding is enabling developers to investigate CRISPR-based approaches across a broader range of genetic diseases and applications.
Government funding and supportive regulatory frameworks boosting gene editing research
Public-sector funding and evolving regulatory frameworks are strengthening the research environment for the CRISPR-based gene editing market by reducing barriers to technological development and clinical investigation. Government-backed research programs can provide resources for basic gene-editing studies, disease modeling, safety assessment, and translational research, while clearer regulatory pathways can help developers understand requirements for advancing gene-editing candidates. Increased institutional support is also encouraging collaboration among academic researchers, biotechnology organizations, and healthcare stakeholders, expanding access to specialized expertise and research infrastructure. These conditions facilitate continued development of CRISPR platforms across therapeutic and research applications.
Expansion of clinical gene therapy pipelines driving commercialization of CRISPR technologies
The expanding pipeline of gene therapy programs is creating a stronger pathway from CRISPR research toward commercial applications. Within the CRISPR-based gene editing market, growing clinical activity is increasing the need for technologies capable of delivering targeted genetic modifications while addressing considerations such as editing accuracy, delivery, safety, and durability of therapeutic effects. As more candidates progress through preclinical and clinical development, developers are gaining practical insights that can improve editing platforms and associated delivery systems. The movement of CRISPR technologies into therapeutic development is also expanding opportunities across disease-specific treatments, manufacturing capabilities, clinical research services, and supporting gene-editing infrastructure.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising genetic disorder prevalence and biotech investment accelerating CRISPR adoption | 2.00% | High | North America | High | Near Term |
| Government funding and supportive regulatory frameworks boosting gene editing research | 1.80% | High | Asia Pacific, Europe | Medium | Mid Term |
| Expansion of clinical gene therapy pipelines driving commercialization of CRISPR technologies | 1.70% | High | North America, Europe | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America accounted for the largest share of the CRISPR-based gene editing market at 44.10% in 2026, supported by advanced biomedical research infrastructure, substantial investment in biotechnology, and strong integration of gene-editing technologies into pharmaceutical and academic research. Leading research institutions and specialized laboratories provide a robust environment for developing therapeutic applications, agricultural innovations, and functional genomics solutions. Continued progress in precision medicine and genetic disease research is increasing demand for sophisticated gene-editing platforms, while established regulatory and clinical research ecosystems facilitate the translation of promising technologies into therapeutic development programs.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing region, fueled by expanding biotechnology capabilities, rising investment in life sciences research, and increasing government support for advanced genomic technologies. Improvements in research infrastructure and growing availability of specialized laboratories are enabling broader adoption of CRISPR-based tools across biomedical research, drug discovery, agriculture, and disease modeling. The region's expanding biopharmaceutical sector and growing focus on precision medicine are creating additional demand for gene-editing technologies. Increasing collaboration between research institutions and healthcare organizations is also helping accelerate the development and application of CRISPR-based approaches.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Regulatory Quality FocusGermany emphasizes robust regulatory compliance and high-quality gene editing research for clinical and industrial applications. The country's pharmaceutical and academic collaborations support validated CRISPR workflows while strengthening translational research and advanced therapeutic development.
France 🇫🇷
Translational Research NetworkFrance supports CRISPR-based gene editing through coordinated biomedical research programs and public-private partnerships. French institutions focus on translating laboratory discoveries into therapeutic candidates while maintaining rigorous ethical and regulatory standards for genome editing.
Italy 🇮🇹
Specialized Research ExpansionItaly is expanding CRISPR-based gene editing capabilities through specialized academic centers and collaborative life sciences initiatives. Research priorities include rare disease therapies, molecular diagnostics, and improved laboratory infrastructure that enables broader clinical research participation.
Japan 🇯🇵
Precision Therapeutics FocusJapan advances CRISPR-based gene editing by integrating precision medicine initiatives with regenerative medicine research. Domestic organizations are refining safe genome editing approaches while expanding partnerships that support innovative therapeutic platforms and clinical validation.
South Korea 🇰🇷
Biotech Innovation PipelineSouth Korea strengthens its CRISPR-based gene editing ecosystem through biotechnology startups, government-backed research, and expanding clinical capabilities. Investment in genome engineering platforms supports therapeutic innovation alongside applications in diagnostics and agricultural biotechnology.
United States 🇺🇸
Clinical Translation HubThe U.S. prioritizes expanding CRISPR-based gene editing through clinical research, biotechnology investment, and scalable manufacturing capabilities. Strong collaboration between research institutions and industry continues to accelerate therapeutic development across rare diseases, oncology, and precision medicine applications.
Segment Leadership and Growth Trends
CRISPR-based Gene Editing Market Share (%), by End Use, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportEnd Use Segment Analysis: Pharmaceutical & Biotechnology Companies (Largest Segment) vs Contract Research Organizations (Fastest-Growing Segment)
Pharmaceutical & biotechnology companies held the largest share of the CRISPR-based gene editing market in 2026 at 48.99%, reflecting their substantial role in developing gene-editing-based therapeutics and advancing precision medicine research. These organizations have the resources, research capabilities, and development infrastructure needed to evaluate CRISPR technologies across therapeutic discovery and validation programs. Increasing interest in targeted genetic interventions and the broader expansion of biotechnology research are reinforcing demand for gene-editing tools within this end-use group.
Contract research organizations are experiencing faster expansion as pharmaceutical and biotechnology developers increasingly rely on external expertise for specialized research activities. CROs can provide access to gene-editing capabilities, technical personnel, experimental infrastructure, and flexible project support without requiring organizations to build all capabilities internally. The growing complexity of gene-editing research and the value of specialized outsourcing are therefore broadening the role of CROs throughout the development workflow.
Product & Service Segment Analysis: Products (Largest Segment) vs Services (Fastest-Growing Segment)
Products represented the largest share of the CRISPR-based gene editing market in 2026, reflecting continued demand for gene-editing reagents, instruments, delivery components, and other specialized tools required to conduct research and therapeutic development. Researchers depend on reliable and precise product solutions to perform targeted genetic modifications, evaluate outcomes, and advance experimental programs. Increasing adoption of gene-editing approaches across research settings is sustaining demand for specialized products that support reproducible workflows.
Services are gaining traction as organizations seek access to specialized gene-editing expertise without making extensive investments in internal infrastructure. Outsourced services can support experimental design, gene-editing execution, validation, screening, and other technically demanding activities, helping research teams accelerate development while managing operational complexity. The increasing specialization of CRISPR workflows and the need for efficient access to advanced capabilities are supporting the rapid expansion of service-based offerings.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| End Use | Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations | Pharmaceutical & Biotechnology Companies | Contract Research Organizations |
| Product & Service | Products, Services | Products | Services |
| Application | Biomedical, Agricultural Applications | Biomedical | Biomedical |
Competitive Landscape and Market Positioning
Prominent players in the CRISPR-based gene editing market:
1. Thermo Fisher Scientific Inc. (United States)
2. Merck KGaA (Germany)
3. Danaher Corporation (United States)
4. Revvity Inc. (United States)
5. GenScript Biotech Corporation (China)
6. Bio-Rad Laboratories Inc. (United States)
7. Bio-Techne Corporation (United States)
8. New England Biolabs Inc. (United States)
9. OriGene Technologies Inc. (United States)
10. Integrated DNA Technologies Inc. (United States)
Breakthroughs in genetic engineering are rapidly advancing the CRISPR-based gene editing market, with expanded focus on therapeutic and agricultural applications. Continuous experimentation is improving precision, delivery systems, and safety profiles of gene editing tools. Collaborative research frameworks are accelerating discovery-to-application timelines. New therapeutic pipelines are emerging across rare and complex genetic disorders.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Merck KGaA (Germany) | |||||||
| Danaher Corporation (United States) | |||||||
| Revvity Inc. (United States) | |||||||
| GenScript Biotech Corporation (China) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| Bio-Techne Corporation (United States) | |||||||
| New England Biolabs Inc. (United States) | |||||||
| OriGene Technologies Inc. (United States) | |||||||
| Integrated DNA Technologies Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Intellia Therapeutics | Feb-26 | Intellia Therapeutics initiated a rolling FDA submission for its lead in vivo CRISPR therapy, lonvo-z, targeting hereditary angioedema. Following positive Phase 3 clinical outcomes demonstrating reduced attack frequency, this filing represents a critical milestone in moving advanced CRISPR-based gene editing toward commercialization and broad therapeutic adoption for hereditary conditions. |
| 4basebio PLC | Feb-26 | 4basebio launched a high-capacity enzymatic single-stranded DNA (ssDNA) platform to support next-generation gene-editing workflows. By providing a scalable solution for nucleic acid manufacturing, this platform enhances the precision and safety profiles required for advanced cell engineering, filling a strategic infrastructure gap in the development of sophisticated genetic therapies. |
| Arbor Biotechnologies | Jan-26 | Arbor Biotechnologies secured $74 million in funding to accelerate the clinical development of ABO-101, a CRISPR-based therapy for primary hyperoxaluria type 1. This capital infusion supports the initiation of Phase 1 trials, reinforcing the company's competitive position as it transitions from early-stage research to clinical-stage assessment within the gene-editing therapeutics market. |
| Axelyf | Jan-26 | Axelyf launched its operations to focus on advanced lipid nanoparticle (LNP) delivery systems, utilizing its proprietary machine learning platform, ANNA. By optimizing LNP formulations for precise gene-editing delivery, the company addresses the critical technical challenge of tissue-specific targeting, thereby expanding the potential scope and efficacy of nucleic acid and CRISPR-based therapeutic applications. |
| Mammoth Biosciences | Dec-25 | Mammoth Biosciences entered a strategic collaboration with Regeneron Pharmaceuticals valued at up to $370 million per target. By licensing its ultracompact CRISPR platform, Mammoth aims to expand the therapeutic reach of gene editing into diverse tissues beyond the liver, significantly scaling its technology adoption and validating its proprietary platform within the high-value pharmaceutical sector. |
| Danaher | May-25 | Danaher leveraged its proprietary Business System to reduce the production timeline for a personalized mRNA-based CRISPR therapy to under six months. This operational milestone demonstrates a significant improvement in manufacturing speed and agility, highlighting the potential for accelerated, custom genetic treatment delivery in rare disease applications. |
| Kytopen | Apr-25 | Kytopen and Aldevron formed a strategic partnership to integrate Nanoplasmid and Flowfect Tx technologies. By optimizing the upstream and downstream processes for T-cell engineering, this collaboration increases manufacturing yields and streamlines GMP production, directly addressing scalability constraints for CRISPR-mediated advanced cell therapies. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
CRISPR-based Gene Editing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Gene Editing Modality | CRISPR-Cas9, Base Editing, Prime Editing, CRISPR-Cas12, CRISPR-Cas13 |
| Delivery Method | Viral Delivery, Lipid Nanoparticle Delivery, Polymer-Based Delivery, Electroporation, Other Non-Viral Delivery |
| Development Stage | Discovery & Preclinical, Phase I, Phase II, Phase III, Commercialized |
CRISPR-based Gene Editing Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Therapeutic Pipeline Opportunity Assessment |
|
| Intellectual Property Landscape Assessment |
|
| Gene Editing Commercialization Outlook |
|
Need a different cut of the data?
Request Custom ResearchHow much is the CRISPR-based gene editing market worth?
How will the CRISPR-based gene editing industry grow in terms of size and CAGR by 2036?
How are expanding clinical gene therapy pipelines influencing commercialization in the CRISPR-based gene editing market?
Why are government funding and supportive regulatory frameworks important for CRISPR market expansion?
Why do Pharmaceutical & Biotechnology Companies dominate the CRISPR-based gene editing market?
How are Contract Research Organizations driving growth in the CRISPR-based gene editing market?
Why does North America lead the CRISPR-based gene editing market?
What is driving Asia Pacific growth in CRISPR gene editing market?
What are the key competitors in the CRISPR-based gene editing landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization